Targeting immune imbalance in recurrent miscarriage: Focus on cyclosporine A

Summaries 3 min 544

Font Size

Created On: 29/04/2026

Recurrent miscarriage, particularly unexplained recurrent spontaneous abortion, remains a key challenge in reproductive medicine.

See All

Key take away

Low-dose cyclosporine A improves pregnancy success rates in immune-related recurrent miscarriage by restoring immune balance and enhancing protective antibody responses.

Background

Recurrent miscarriage, particularly unexplained recurrent spontaneous abortion, remains a key challenge in reproductive medicine. Emerging evidence suggests that cyclosporine A (CsA)—an immunomodulatory agent—may enhance pregnancy success rates by correcting immune dysfunction. This study determined the impact of low-dose CsA therapy on immune system markers and clinical pregnancy outcomes in women with immune-mediated adverse pregnancies.

Method

This retrospective study analyzed patients treated at a tertiary care center in Shenzhen, China. Women with immune-related pregnancy complications received CsA therapy, and data were collected on:

Cytokine profiles (interleukin [IL]-2, IL-4, IL-6, IL-10, IL-17, interferon-gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α])
Lymphocyte subpopulations (CD3+, CD4+, CD8+)
Blocking antibody levels
Blood CsA concentration

The goal was to identify the optimal therapeutic range of CsA and assess its role in improving pregnancy outcomes.

Result

Among 661 patients, 279 attained successful pregnancies following CsA treatment.

Substantial increases in CD3+, CD4+, and CD8+ blocking antibodies were noted, with CD3+ and CD4+ strongly linked with pregnancy success.
Receiver operating characteristic (ROC) curve analysis identified CD3+ and CD4+ antibody elevation as strong predictors of successful pregnancy outcomes.
Pro-inflammatory cytokines (IL-2, IL-6, IL-17, IFN-γ, TNF-α) and anti-inflammatory cytokines (IL-4, IL-10) markedly dropped after treatment, depicting immune modulation.
Key immune ratios (IL-2/IL-10, IFN-γ/IL-10) declined, reflecting improved immune tolerance in pregnancy.

Most subjects maintained CsA blood levels between 10–70 ng/mL, suggesting a safe and effective therapeutic range.

Conclusion

Low-dose cyclosporine A depicted remarkable potential in improving pregnancy success rates in women with immune-related recurrent miscarriage. By regulating cytokine balance, enhancing blocking antibodies, and restoring immune tolerance, CsA offers a promising strategy for tackling adverse pregnancy outcomes linked to immune dysfunction.